Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients A systematic review and meta-Analysis

Young Ju Won, Byung Gun Lim, Dong Kyu Lee, Heezoo Kim, Myoung Hoon Kong, Il Ok Lee

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Background: Previous studies have shown that sugammadex, a modified g-cyclodextrin, is a well-Tolerated agent for the reversal of neuromuscular blockade (NMB) induced by a steroidal neuromuscular blocking drug in adult patients. However, its use has not been reviewed in pediatric patients. The aim of this meta-Analysis was to evaluate the efficacy and safety of sugammadex in the reversal of rocuronium-induced NMB during surgery under general anesthesia in pediatric patients. Methods: A literature search was performed using the Pubmed, EMBASE: Drugs and pharmacology, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. Analysis was conducted using RevMan 5.3. Data collected from different trials were pooled; the weighted mean difference or the pooled risk ratio and the corresponding 95% confidence interval (CI) were used for analysis, and heterogeneity (I2) assessment was performed. Results: Six randomized controlled trials comparing 253 pediatric patients (age range, 2-18 years) were included in the final analysis. The mean time taken to reach a train-of-four ratio of ≥0.9 was significantly shorter in the sugammadex groups (2 and 4 mg/kg) than in the control group (neostigmine or placebo), although the heterogeneity was high. The weighted mean differences of the 2 and 4mg/kg sugammadex groups were -7.15 (95% CI: -10.77 to -3.54; I2=96%; P=0.0001) and -17.32 (95% CI: -29.31 to -5.32; I2=98%; P=0.005), respectively. The extubation time in the sugammadex group was shorter than that in the control group; the weighted mean difference of the sugammadex group was -6.00 (95% CI: -11.46 to -0.53; I2=99%; P=0.03). There was no significant difference between the groups in terms of the incidence of postanesthetic adverse events; the pooled risk ratio was 0.67 (95% CI: 0.27-1.71; I2=59%; P=0.41). Conclusion: We suggest that sugammadex is fast and effective in reversing rocuronium-induced NMB in pediatric patients. Although there was no evidence of a higher incidence of adverse events with sugammadex compared to that with neostigmine or placebo, much more data regarding the safety of sugammadex in pediatric patients may be still required.

Original languageEnglish
JournalMedicine (United States)
Issue number34
Publication statusPublished - 2016


  • Adolescent
  • Child
  • Neostigmine
  • Neuromuscular blockade
  • Preschool
  • Reversal
  • Sugammadex

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients A systematic review and meta-Analysis'. Together they form a unique fingerprint.

Cite this